アログリプチン錠の特別薬物使用監視「2型糖尿病：α-GIとの単剤療法／併用療法」

基本情報

NCT ID

NCT01945216

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

3,317

治験依頼者名

Takeda

概要

The purpose of this study is to determine the safety and efficacy of long-term treatment with alogliptin (Nesina) in patients with type 2 diabetes mellitus who responded inadequately to diet therapy and exercise therapy alone, or a combination of diet therapy, exercise therapy, and α-glucosidase inhibitor. In addition, examining the safety and efficacy of alogliptin in patients with renal impairment, information on the appropriate dosage of alogliptin according to the severity of impaired renal function should be collected.

対象疾患

介入

依頼者（Sponsor）